Spyre Therapeutics
SYRE
SYRE
32 hedge funds and large institutions have $38.1M invested in Spyre Therapeutics in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
3% less funds holding
Funds holding: 33 → 32 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Holders
32
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$137K | |
| 2 | +$64K | |
| 3 | +$64K | |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$49.3K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$45.5K |
Top Sellers
| 1 | -$653K | |
| 2 | -$61K | |
| 3 | -$55K | |
| 4 |
Wells Fargo
San Francisco,
California
|
-$17.8K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$12.5K |